WINTON GROUP Ltd Grows Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

WINTON GROUP Ltd increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 94.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,005 shares of the biopharmaceutical company's stock after buying an additional 9,210 shares during the quarter. WINTON GROUP Ltd's holdings in Cytokinetics were worth $894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its holdings in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in Cytokinetics during the 4th quarter worth approximately $29,000. AlphaQuest LLC increased its stake in Cytokinetics by 113,500.0% during the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp raised its holdings in shares of Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 671 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 842 shares during the period.

Remove Ads

Insider Transactions at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $45.92, for a total value of $91,840.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at approximately $5,329,980.32. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Andrew Callos sold 3,341 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total value of $144,565.07. Following the transaction, the executive vice president now directly owns 64,434 shares of the company's stock, valued at $2,788,059.18. The trade was a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,834 shares of company stock valued at $2,560,525. 3.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on CYTK. Royal Bank of Canada lifted their price objective on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a research note on Wednesday, December 18th. Citigroup started coverage on Cytokinetics in a research note on Friday, February 7th. They issued a "buy" rating and a $86.00 target price on the stock. Stifel Nicolaus initiated coverage on Cytokinetics in a report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price on the stock. Morgan Stanley set a $67.00 price target on Cytokinetics in a report on Friday, March 7th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $78.00 price objective on shares of Cytokinetics in a research note on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cytokinetics has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Cytokinetics Trading Up 1.9 %

NASDAQ CYTK traded up $0.77 on Thursday, reaching $41.02. The stock had a trading volume of 580,478 shares, compared to its average volume of 1,521,517. Cytokinetics, Incorporated has a 12-month low of $37.46 and a 12-month high of $75.71. The stock has a fifty day moving average price of $45.34 and a two-hundred day moving average price of $49.23. The firm has a market capitalization of $4.86 billion, a price-to-earnings ratio of -7.62 and a beta of 0.95. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.